Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMTXNASDAQ:LENZNASDAQ:NVAXNASDAQ:OYST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMTXImmatics$6.12-0.3%$4.91$3.30▼$13.37$746.32M0.83654,727 shs536,153 shsLENZLENZ Therapeutics$29.00-2.0%$26.94$16.28▼$38.93$816.23M0.42190,618 shs156,488 shsNVAXNovavax$6.94-2.9%$6.70$5.01▼$17.81$1.12B2.816.57 million shs5.16 million shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMTXImmatics-0.33%+2.51%+34.21%+34.51%-53.35%LENZLENZ Therapeutics-1.96%-9.26%+4.96%+13.95%+55.00%NVAXNovavax-2.94%-6.85%+16.44%-13.14%-56.24%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMTXImmatics2.612 of 5 stars3.63.00.00.03.41.70.0LENZLENZ Therapeutics1.6494 of 5 stars3.61.00.00.02.80.80.0NVAXNovavax3.8658 of 5 stars3.32.00.04.72.70.80.6OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMTXImmatics 3.20Buy$14.67139.65% UpsideLENZLENZ Therapeutics 3.17Buy$46.6060.69% UpsideNVAXNovavax 2.50Moderate Buy$19.20176.66% UpsideOYSTOyster Point Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OYST, NVAX, LENZ, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.005/8/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/16/2025LENZLENZ TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.004/14/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight ➝ Overweight$38.00 ➝ $51.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/20/2025LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$44.00 ➝ $47.003/18/2025LENZLENZ TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMTXImmatics$144.15M5.16N/AN/A$2.88 per share2.13LENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/ANVAXNovavax$1.21B0.93N/AN/A($6.04) per share-1.15OYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMTXImmatics-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%8/12/2025 (Estimated)LENZLENZ Therapeutics-$124.65M-$1.77N/AN/AN/AN/A-58.48%-55.50%8/13/2025 (Estimated)NVAXNovavax-$545.06M$2.65N/A86.752.85-32.18%N/A-17.05%8/14/2025 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/ALatest OYST, NVAX, LENZ, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/7/2025Q1 2025LENZLENZ Therapeutics-$0.55-$0.53+$0.02-$0.53N/AN/A3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million3/19/2025Q4 2024LENZLENZ Therapeutics-$0.42-$0.46-$0.04-$0.46N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMTXImmaticsN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMTXImmaticsN/A3.983.98LENZLENZ TherapeuticsN/A28.6328.63NVAXNovavaxN/A0.930.93OYSTOyster Point Pharma8.493.353.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMTXImmatics64.41%LENZLENZ Therapeutics54.32%NVAXNovavax53.04%OYSTOyster Point Pharma96.70%Insider OwnershipCompanyInsider OwnershipIMTXImmatics3.30%LENZLENZ Therapeutics6.90%NVAXNovavax1.00%OYSTOyster Point Pharma17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMTXImmatics260121.55 million115.42 millionOptionableLENZLENZ Therapeutics11028.15 million16.94 millionN/ANVAXNovavax1,990161.97 million158.58 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionableOYST, NVAX, LENZ, and IMTX HeadlinesRecent News About These CompaniesAviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and InnovationApril 1, 2025 | finance.yahoo.comBillion-dollar real estate bet could spark a biotech revivalMarch 21, 2025 | bizjournals.comVibrant Wintertime Flower At Oyster Point: PhotoFebruary 20, 2025 | msn.comNext phase of Kilroy's big Oyster Point project sees interest beyond biotechFebruary 11, 2025 | bizjournals.comThe Oyster Point Gallery presents "The Cut-Outs" by Gary Steven GrovesJanuary 14, 2025 | newjerseystage.comTed Danson, Kristen Bell and D’Arcy Carden Reunite at “A Man on the Inside ”Premiere 4 Years After “The Good Place ”(Exclusive)November 12, 2024 | msn.comTransmucosal Drug Delivery Pipeline Report 2024 - Stages of Development, Segments, Region and Countries, Regulatory Path and Key CompaniesNovember 12, 2024 | finance.yahoo.comHow A.I. Is Disrupting Pharma: The High-Stakes Race to Revolutionize Drug DiscoveryNovember 12, 2024 | observer.comEyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate DevelopmentsNovember 7, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy RatingNovember 7, 2024 | markets.businessinsider.comIndian stocks rally over Trump's win; Sensex jumps 901 pointsNovember 6, 2024 | malaysiasun.comUS election: Treasuries slip on election day as volatility hits one-year highNovember 6, 2024 | moneycontrol.comDaily Voice: This fund manager is strategically accumulating positions in healthcare, consumer staples in recent market pullbackNovember 6, 2024 | moneycontrol.comUS Elections| Why outcome does not matter in the long-run; market strategist makes a $19-million pointNovember 5, 2024 | moneycontrol.comHow to Talk About Oysters Like You Know What You're Talking AboutOctober 31, 2024 | foodandwine.comEyePoint Pharma Prices Public Offering Of About 12.73 Mln Shares At $11.00/shrOctober 30, 2024 | markets.businessinsider.comScotiabank Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)October 29, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals Shares Rise 35% on Positive Clinical Trial Data for DuravyuOctober 29, 2024 | marketwatch.comPositive Outlook for EyePoint Pharmaceuticals: Phase 3 LUGANO Trial for DURAVYU Boosts Buy RatingOctober 26, 2024 | markets.businessinsider.comPositive Outlook for EyePoint Pharmaceuticals Amid Promising Phase 3 Trials for DuravyuOctober 25, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOYST, NVAX, LENZ, and IMTX Company DescriptionsImmatics NASDAQ:IMTX$6.12 -0.02 (-0.33%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$6.04 -0.08 (-1.37%) As of 06/13/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.LENZ Therapeutics NASDAQ:LENZ$29.00 -0.58 (-1.96%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$29.08 +0.08 (+0.28%) As of 06/13/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Novavax NASDAQ:NVAX$6.94 -0.21 (-2.94%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.02 +0.07 (+1.08%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.Oyster Point Pharma NASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
